» Articles » PMID: 31619203

Poorly Differentiated Neuroendocrine Rectal Carcinoma with Uncommon Immune-histochemical Features and Clinical Presentation with a Subcutaneous Metastasis, Treated with First Line Intensive Triplet Chemotherapy Plus Bevacizumab FIr-B/FOx Regimen: An...

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2019 Oct 18
PMID 31619203
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroendocrine tumors (NETs) are heterogeneous, widely distributed tumors arising from neuroendocrine cells. Gastrointestinal (GI)-NETs are the most common and NETs of the rectum represent 15, 2% of gastrointestinal malignancies. Poorly differentiated neuroendocrine carcinomas of the GI tract are uncommon. We report a rare case of poorly differentiated locally advanced rectal neuroendocrine carcinoma with nodal and a subcutaneous metastasis, with a cytoplasmic staining positive for Synaptophysin and Thyroid Transcription Factor-1.

Case Presentation: A 72-year-old male presented to hospital, due to lumbar, abdominal, perineal pain, and severe constipation. A whole-body computed tomography scan showed a mass of the right lateral wall of the rectum, determining significant reduction of lumen caliber. It also showed a subcutaneous metastasis of the posterior abdominal wall. Patient underwent a multidisciplinary evaluation, diagnostic and therapeutic plan was shared and defined. The pathological examination of rectal biopsy and subcutaneous nodule revealed features consistent with small-cell poorly differentiated neuroendocrine carcinoma. First line medical treatment with triplet chemotherapy and bevacizumab, according to FIr-B/FOx intensive regimen, administered for the first time in this young elderly patient affected by metastatic rectal NEC was highly active and tolerable, as previously reported in metastatic colo-rectal carcinoma (MCRC). A consistent rapid improvement in clinical conditions were observed during treatment. After 6 cycles of treatment, CT scan and endoscopic evaluation showed clinical complete response of rectal mass and lymph nodes; patient underwent curative surgery confirming the pathologic complete response at PFS 9 months.

Discussion And Conclusions: This case report of a locally advanced rectal NEC with an unusual subcutaneous metastasis deserves further investigation of triplet chemotherapy-based intensive regimens in metastatic GEP NEC.

Citing Articles

Resection of primary lesion with chemotherapy improves the survival of patients with metastatic colorectal neuroendocrine carcinoma.

Wang Q, Yin R, Tang W, Li C, Zheng H, Zhang X Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022; 51(5):594-602.

PMID: 36581574 PMC: 10264974. DOI: 10.3724/zdxbyxb-2021-0387.


Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy.

Bruera G, DAndrilli A, Simmaco M, Guadagni S, Rendina E, Ricevuto E Front Oncol. 2020; 10:1155.

PMID: 32850329 PMC: 7417602. DOI: 10.3389/fonc.2020.01155.


Squamous cell anal cancer: Management and therapeutic options.

Pessia B, Romano L, Giuliani A, Lazzarin G, Carlei F, Schietroma M Ann Med Surg (Lond). 2020; 55:36-46.

PMID: 32461801 PMC: 7240186. DOI: 10.1016/j.amsu.2020.04.016.

References
1.
Ficorella C, Bruera G, Cannita K, Porzio G, Lanfiuti Baldi P, Tinari N . Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. Clin Colorectal Cancer. 2012; 11(4):229-37. DOI: 10.1016/j.clcc.2012.05.001. View

2.
Bruera G, Massacese S, Galvano A, Dal Mas A, Guadagni S, Calvisi G . Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer. Oncotarget. 2018; 9(29):20339-20350. PMC: 5945545. DOI: 10.18632/oncotarget.24861. View

3.
Shafqat H, Ali S, Salhab M, Olszewski A . Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum. 2015; 58(3):294-303. DOI: 10.1097/DCR.0000000000000298. View

4.
Bialecki M, Bialecka A, Mecinska-Jundzill K, Adamska U, Kasperska A, Czajkowski R . Imaging in a rare case of neuroendocrine tumour with skin metastases. Pol J Radiol. 2018; 83:e63-e67. PMC: 6047099. DOI: 10.5114/pjr.2018.73307. View

5.
Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View